LON:ADN - 1724525 (ADN.L) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0
+0.30 (1.20%)

This chart shows the closing price for ADN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 1724525 (ADN.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADN

Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for 1724525 (ADN.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.

This chart shows the closing price for ADN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in 1724525 (ADN.L). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/11/2017MacquarieReiterated RatingNeutralGBX 271
7/20/2017BarclaysBoost Price TargetUnderweightGBX 260 ➝ GBX 285
7/18/2017BNP ParibasReiterated RatingNeutralGBX 300
7/11/2017Jefferies Financial GroupBoost Price TargetHoldGBX 287 ➝ GBX 302
6/15/2017Berenberg BankInitiated CoverageHoldGBX 290
6/7/2017Morgan StanleyUpgradeEqual weightGBX 260 ➝ GBX 332
5/15/2017MacquarieReiterated RatingNeutralGBX 271
5/8/2017MacquarieReiterated RatingNeutralGBX 271
5/4/2017Numis SecuritiesDowngradeAddGBX 332 ➝ GBX 338
5/2/2017Peel HuntReiterated RatingHoldGBX 280
5/2/2017Shore CapitalReiterated RatingSell
5/2/2017Numis SecuritiesReiterated RatingBuyGBX 332
5/2/2017Liberum CapitalReiterated RatingBuyGBX 332
4/10/2017Jefferies Financial GroupReiterated RatingHoldGBX 287
4/7/2017Royal Bank of CanadaUpgradeOutperformGBX 300
4/4/2017UBS GroupReiterated RatingSellGBX 235
3/27/2017BNP ParibasReiterated RatingNeutralGBX 280
3/27/2017Peel HuntReiterated RatingHoldGBX 280
3/14/2017Jefferies Financial GroupReiterated RatingHoldGBX 287
3/9/2017Numis SecuritiesDowngradeAddGBX 332
3/7/2017Beaufort SecuritiesDowngradeHold
3/7/2017Royal Bank of CanadaBoost Price TargetSector PerformerGBX 285 ➝ GBX 300
3/6/2017Shore CapitalReiterated RatingSell
3/6/2017Numis SecuritiesUpgradeBuyGBX 345
3/6/2017CitigroupUpgradeNeutralGBX 280
3/6/2017Jefferies Financial GroupUpgradeHoldGBX 221 ➝ GBX 287
3/6/2017Peel HuntReiterated RatingHoldGBX 280
3/6/2017Liberum CapitalUpgradeBuyGBX 261 ➝ GBX 332
2/23/2017UBS GroupLower Price TargetSellGBX 245 ➝ GBX 230
2/8/2017Royal Bank of CanadaUpgradeSector PerformerGBX 290 ➝ GBX 285
2/3/2017The Goldman Sachs GroupReiterated RatingSellGBX 245
2/3/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 270 ➝ GBX 250
2/2/2017Numis SecuritiesReiterated RatingHoldGBX 270
2/2/2017Peel HuntLower Price TargetHoldGBX 330 ➝ GBX 280
2/2/2017Liberum CapitalReiterated RatingHoldGBX 261
2/2/2017Shore CapitalReiterated RatingSell
2/1/2017Jefferies Financial GroupReiterated RatingUnderperformGBX 221
1/27/2017Liberum CapitalReiterated RatingHoldGBX 261
1/26/2017Morgan StanleyLower Price TargetUnderweightGBX 273 ➝ GBX 267
1/24/2017The Goldman Sachs GroupBoost Price TargetSellGBX 235 ➝ GBX 245
(Data available from 1/19/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
1724525 (ADN.L) logo
Aberdeen Asset Management PLC is a United Kingdom-based asset manager. The Company operates through asset management for reporting and control purposes. The Company is managed as a single asset management business, with multiple investment strategies of equities, fixed income and property, complemented by a solutions business, which provides multi asset, alternatives and quantitative investment capabilities. These strategies are managed across a range of products, distribution channels and geographic regions. The Company holds investments in seed capital investments, investments in certain Aberdeen-managed funds to hedge deferred fund awards and other investments. The Company operates in approximately 20 countries. Its operations span across Asia Pacific, Australia, the United Kingdom, the United States, the Middle East and Europe, among others.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

3,090,000 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 1724525 (ADN.L)?

The following sell-side analysts have issued reports on 1724525 (ADN.L) in the last year:
View the latest analyst ratings for ADN.

What is the current price target for 1724525 (ADN.L)?

0 Wall Street analysts have set twelve-month price targets for 1724525 (ADN.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for 1724525 (ADN.L) in the next year.
View the latest price targets for ADN.

What is the current consensus analyst rating for 1724525 (ADN.L)?

1724525 (ADN.L) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADN.

What other companies compete with 1724525 (ADN.L)?

Other companies that are similar to 1724525 (ADN.L) include S&P SmallCap 600/Citigroup Growth Index, (AURR.L), (BAV.L), (BNNP), (BVII), (CBNR), (DGTC), (DTOR), (EDW.V), (EFLO), (FOHL), (FSN.V), (FTE.V), (GFIR.L) and (GPK.L).

How do I contact 1724525 (ADN.L)'s investor relations team?

1724525 (ADN.L)'s physical mailing address is 10 Queens Terrace, ABERDEEN, AB10 1XL, United Kingdom. The company's listed phone number is +44-1224-631999. The official website for 1724525 (ADN.L) is www.aberdeen-asset.com.